

August 17, 2020
Sawai Pharmaceutical Co., Ltd.

Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths

Osaka, Japan – August 17, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 4 generic drugs with 13 strengths. The 2 compounds marked with an asterisk below are approved for the first time as generics.

The list of approved products:

1. Pregabalin OD Tablets, Capsules

Generic name:	Pregabalin*	Strengths:	OD Tablets, Capsules: 25mg, 75mg, 150mg
Brand products:	Lyrica® OD Tablets 25mg, 75mg, 150mg, Lyrica® Capsules 25mg, 75mg, 150mg		

2. Rivastigmine Tapes

Generic name:	Rivastigmine*	Strengths:	4.5mg, 9mg, 13.5mg, 18mg
Brand products:	EXELON® PATCH 4.5mg, 9mg, 13.5mg, 18mg, RIVASTACH® Patches 4.5mg, 9mg, 13.5mg, 18mg		

3. Bortezomib for Injection

Generic name:	Bortezomib	Strengths:	3mg
Brand products:	VELCADE® Injection 3mg		

4. Famotidine Intravenous Injection

Generic name:	Famotidine	Strengths:	10mg, 20mg
Brand products:	Gaster® Injection 10mg, 20mg		

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

◆ Contact Information ◆

PR / IR Office, Sawai Pharmaceutical Co., Ltd.

E-mail : koho@sawai.co.jp